Indication
As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum‑containing regimen.
Medicine details
- Medicine name:
- dostarlimab (Jemperli)-
- SMC ID:
- SMC2918
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Reassessment
- Publication due date:
- TBC
- SMC meeting date:
- TBC